September 20th 2024
The approval of amivantamab plus carboplatin and pemetrexed is supported by data from the phase 3 MARIPOSA-2 trial.
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Improved OS Observed When Aggressive Radiation, Surgery Is Added to NSCLC Therapy
January 2nd 2019Adding aggressive, local radiation or surgery to frontline systemic therapy in patients with stage IV NSCLC whose disease has spread to a limited number of sites resulted in improved overall survival, according to findings presented by Daniel Gomez, MD, and colleagues at the 60th Annual Meeting of the American Society for Radiation Oncology in San Antonio, Texas.
Read More
Findings for the Combination of Anti-TIM-3 and Anti-PD-1 in Melanoma and Lung Cancer
December 27th 2018Diwakar Davar, MBBS, MSc, discusses how data from the phase I trial of TSR-022, an anti-TIM-3 monoclonal antibody, and TSR-042, an anti-PD-1 agent, impact the treatment of patients with both melanoma and lung cancer.
Watch
Decision Deadline for First-Line Pembrolizumab in NSCLC Extended by FDA
December 27th 2018The review period for a supplemental biologics license application for first-line treatment with pembrolizumab monotherapy for the treatment of patients with locally advanced or metastatic nonsquamous or squamous non–small cell lung cancer with PD-L1 expression (tumor proportion score) of ≥1% and no <em>EGFR </em>or <em>ALK </em>genomic tumor aberrations has been extended by the FDA, according to a press release by Merck, the manufacturer of pembrolizumab.
Read More
Quantifying the Benefits of Precision Oncology
December 14th 2018Precision medicine has produced some dramatic successes in patients with advanced cancer. With developments in molecular profiling, targeted therapies are being applied to multiple tumors, most notably in advanced melanoma, NSCLC, and several types of leukemia. Alison Schram, MD, and David M. Hyman, MD, point out the challenges in determining the proportion of patients who will benefit from receiving targeted therapies.
Read More
Promise Is Seen in Newer EGFR TKIs to Overcome Resistance in NSCLC
December 11th 2018Acquired resistance to tyrosine kinase inhibitors targeting <em>EGFR</em> mutations in patients with non–small cell lung cancer are leading to next-generation therapies equipped to circumvent the mutations that arise from initial treatment. A review of these mechanisms, and the latest agents being developed to address them, shows that the pipeline holds promise for the future.
Read More
Phase III Trial Evaluating Rova-T in Small Cell Lung Cancer Put on Hold
December 8th 2018The phase III TAHOE trial evaluating rovalpituzumab tesirine as a second-line treatment for patients with advanced small cell lung cancer has been put on hold, based on a recommendation from an Independent Data Monitoring Committee, according to AbbVie, the developer of the investigational antibody-drug conjugate.<br />
Read More
FDA Grants Approval to Frontline Atezolizumab Regimen for NSCLC
December 7th 2018Atezolizumab (Tecentriq) has been approved by the FDA for use in combination with bevacizumab, carboplatin, and paclitaxel as a first-line treatment for patients with metastatic nonsquamous non-small cell lung cancer. This indication excludes patients with <em>EGFR</em>/<em>ALK</em> aberrations.
Read More
FDA Grants Atezolizumab Plus Chemotherapy Regimen Priority Review for Frontline SCLC
December 5th 2018Based on findings from the phase III IMpower133 study, a supplemental biologics license application (sBLA) for atezolizumab (Tecentriq) has been granted a priority review by the FDA for use in combination with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer.
Read More
Trial Investigators Discuss FDA Draft Guidance on Master Protocols
December 1st 2018Complex drug trials that use a single protocol to test either 1 agent against multiple cancers or multiple agents against 1 cancer can make drug testing faster, cheaper, and more informative, particularly when those trials use the data to constantly improve protocols.
Read More
Nivolumab/Ipilimumab Combination Falls Short in Phase III SCLC Trial
November 27th 2018The CheckMate-451 trial missed its primary endpoint of overall survival with the combination of nivolumab and ipilimumab as a maintenance therapy for patients with extensive-stage small cell lung cancer without disease progression following frontline platinum-based chemotherapy.
Read More
Gentzler Details the Changing Landscape for the Treatment of a Patient With NSCLC
November 20th 2018During a <em>Targeted Oncology </em>case-based peer perspectives program, Ryan Gentzler, MD, reviewed with other physicians his clinical considerations for the management of non–small cell lung cancer.
Read More
PFS Improvement Seen in IMpower132 Trial for Patients With NSCLC
November 19th 2018Vassiliki A. Papadimitrakopoulou, MD, Jay and Lori Eisenberg Distinguished Professor of Medicine and section chief of thoracic medical oncology in the department of thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center, discusses the data that were presented at the World Conference on Lung Cancer earlier this year for the IMpower 132 trial comparing the combination of carboplatin/cisplatin plus atezolizumab (Tecentriq) to standard chemotherapy in patients with non–small cell lung cancer.
Watch
Durvalumab Combo Falls Short in Frontline Metastatic NSCLC
November 17th 2018Using durvalumab (Imfinzi) combined with tremelimumab for the frontline treatment of patients with metastatic non–small cell lung cancer did not result in a statistically significant improvement in overall survival compared to standard chemotherapy, according to a press release from AstraZeneca.
Read More
Alectinib Superior to Crizotinib in Frontline Treatment of Asian Patients With ALK+ NSCLC
November 14th 2018Alectinib (Alecensa) was found to be superior to crizotinib (Xalkori) as frontline therapy in Asian patients with untreated <em>ALK</em>-positive advanced non–small cell lung cancer (NSCLC), according to findings reported at the 2018 ESMO Congress.
Read More
Lorlatinib Granted Approval by FDA for ALK+ NSCLC
November 3rd 2018Lorlatinib (Lorbrena) has been granted an accelerated approval by the FDA for use in patients with <em>ALK</em>-positive metastatic non–small cell lung cancer who have progressed on 1 or more ALK tyrosine kinases inhibitors.
Read More
Pembrolizumab Regimen Receives FDA Approval for Frontline Treatment of Squamous NSCLC
October 31st 2018Based on findings from the phase III KEYNOTE-407 trial, pembrolizumab (Keytruda) has been approved by the FDA for use in combination with carboplatin and either paclitaxel or nab-paclitaxel (Abraxane) for the frontline treatment of patients with metastatic squamous non–small cell lung cancer.
Read More
Despite Advances, Interpreting Data From Genomics and Precision Medicine Lags
October 25th 2018I think one of the most important advancements in biomedical technology that has improved our understanding of the complexities of cancer is the ability to sequence the cancer genome for any individual patient, in a rapid and cost-effective manner, to help us make treatment decisions in the clinic.
Read More
Financial Advocacy Grows Under the Value-Based System
October 24th 2018Groundbreaking developments in cancer therapies can change lives, extending survival and sending patients who previously thought their chances were slim into remission. But these therapies come at a cost, and many patients reel at the prospect of heavy financial burdens. To help patients and programs meet the challenges of affording cancer treatments, community cancer centers are expanding the role of financial advocates in their organizations.
Read More
ACCC President Reignites Resilience in Oncology Caregivers
October 23rd 2018Thomas A. Gallo, MS, MDA, president of the Association of Community Cancer Centers, discusses his mission as president to “reflect, renew, and reignite” in order to create a more resilient oncology team for the community.
Watch
OS Benefit Seen in Nonsquamous NSCLC With Triplet Regimen in IMpower130
October 23rd 2018Results from the phase III IMpower130 trial demonstrated a statistically significant improvement in both progression-free survival and overall survival with a triplet regimen of atezolizumab, carboplatin, and nab-paclitaxel compared with chemotherapy alone in patients with previously untreated stage IV nonsquamous non–small cell lung cancer.
Read More
FDA Adds 3 Months to Review Period for Nivolumab Plus Ipilimumab for TMB-High NSCLC
October 23rd 2018Three months have been added on by the FDA to the review period for the supplemental biologics license application for the frontline treatment combination of nivolumab plus low-dose ipilimumab for patients with advanced non–small cell lung cancer with tumor mutational burden ≥10 mutations per megabase.
Read More